GlassScriptPhysician profile
George W Webb
NPI 1750481537
$4,247.69
in general payments reported to CMS, 2019-2025
47 companies · $1,126 in 2025
The $1,126 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $146 · 2021: $342 · 2022: $412 · 2023: $570 · 2024: $1,266 · 2025: $1,126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,962.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $690.30 | 2021-2025 | Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $328.68 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $328.35 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Amgen INC. | $307.49 | 2020-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $237.42 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $208.73 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $186.85 | 2023-2025 | |
| Pfizer INC. | $182.76 | 2019-2024 | |
| Idorsia Pharmaceuticals US INC | $176.67 | 2023-2025 | Quviviq, Quviviq |
| Noven Therapeutics, LLC | $168.91 | 2023-2025 | Xelstrym, Secuado |
| Antares Pharma, INC. | $95.48 | 2019-2025 | Xyosted |
| Dexcom, INC. | $94.10 | 2023-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $89.67 | 2022-2025 | Freestyle Libre 3 |
| Verity Pharmaceuticals INC. | $82.18 | 2024 | Tlando |
| Genentech USA, INC. | $77.53 | 2019-2020 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.